NASDAQ$ZJYL

Jin Medical International Lt · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

ZJYL Q4 2023 — $700.0M revenue

PRC government could disallow the VIE structure, which would likely result in a material change in our operations and, as a result, the. Jin Medical International Lt reported Q4 2023 results. Net income of $2.9M. Headline numbers extracted from the Form 20-F press release; narrative is light because this row was processed without an LLM call.

  • Revenue: $700.0M.
  • Net income: $2.9M.
  • Operating income: $2.9M.
  • Gross profit: $6.8M.

Headline financials

Total Revenue

$19.8M

Previous: $19.2M+3.3%
EPS (adj)

$0.00

Previous: $0.00+0.0%
Capital Expenditures

$114K

Previous: $40.2K+183.7%
Net Income

$2.88M

Previous: $2.71M+6.3%
Operating Income

$2.87M

Previous: $2.13M+34.6%
Gross Profit

$6.78M

Previous: $6.2M+9.5%

Revenue & EPS history

Jin Medical · Revenue · Quarterly

$19.8M

Q4 2023+3.3%vs Q4 2022

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 8 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

-8.9%

Avg return

Earnings day

-3.1%

Avg return

5 days after

+12.7%

Avg return

30 days after

0%

0 / 8 earnings

Positive

+0.0%

Q3 2026

Best reaction

-19.9%

Q2 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2022+0.0%+10.4%+6.7%
Q3 2024+0.0%+10.4%+6.7%
Q3 2026+0.0%+10.4%+6.7%
Q2 2024-7.3%-11.1%-2.5%
Q4 2023-3.8%-7.4%-30.1%
Q2 2022-19.9%-12.4%+38.1%
Q4 2022-19.9%-12.4%+38.1%
Q2 2023-19.9%-12.4%+38.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro